|
Nxstage Medical, Inc. (NXTM) Discloses Form 4 Insider Selling : Exec. Joseph E ... - OTC Outlook |
 |
 |
|
Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Joseph E Jr Turk , President of Nxstage Medical, Inc. sold 2,000 shares on Jun 23, 2015. The Insider selling transaction was disclosed on Jun 24, 2015 to the Securities and Exchange Commission. The shares were sold at $15.36 per share for a total value of $30,720.00 according to InsiderTradingReport.
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) ended Thursday session in red amid volatile trading. The shares closed down 0.02 points or 0.13% at $14.96 with 398,871 shares getting traded. Post opening the session at $15.07, the shares hit an intraday low of $14.88 and an intraday high of $15.1 and the price vacillated in this range throughout the day. The company has a market cap of $946 million and the number of outstanding shares has been calculated to be 63,238,000 shares. The 52-week high of NxStage Medical, Inc. (NASDAQ:NXTM) is $19.63 and the 52-week low is $11.5. Based on the current information, company Insiders own 2.3% of Nxstage Medical, Inc. shares. In the past six months, there is a change of -5.3% in the total insider ownership. Institutional Investors own 96% of Company shares. During last 3 month period, 2.45% of total institutional ownership has changed in the company shares.
The Company has disclosed insider buying and selling activities to the Securities Exchange,The (Chief Executive Officer) of Nxstage Medical, Inc., Burbank Jeffrey H sold 20,000 shares at $$15.56 on June 17, 2015. The Insider selling transaction had a total value worth of $311,200. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. The shares are up 5.81% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $16.22 and the 200 day moving average is recorded at $17.46. S&P 500 has rallied 8.4% during the last 52-weeks. Company has received price target recommendation from many analysts. In the latest statement by the brokerage house, Canaccord Genuity maintains its outlook on NxStage Medical, Inc. (NASDAQ:NXTM). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm raises the price target from $24 per share to $27 per share. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
|
|
PhilHealth expands dialysis coverage - Inquirer.net |
|
|
|
The Philippine Health Insurance Corp. (PhilHealth) will now cover more hemodialysis sessions for those with kidney diseases in a bid to lessen the financial burden of its members.
In a statement, PhilHealth president and chief executive officer Alexander Padilla said that coverage for hemodialysis will be expanded from 45 to 90 sessions per year.
“The PhilHealth Board of Directors approved the expansion due to the growing incidence of kidney diseases in the country and to respond to the increasing clamor from different stakeholders to increase PhilHealth coverage for hemodialysis,” he said.
ADVERTISEMENT
Padilla said the increase in coverage was made possible by the lowering of the case rate amount from P4,000 to only P2,500 per session.
“Based on a series of consultative meetings and dialogues with our stakeholders, our current coverage of P4,000 for hemodialysis is more than enough to cover the treatment cost per session, thus, we are adjusting the case rate amount,” said Padilla.
|
|
|
PhilHealth extends dialysis coverage from 45 to 90 days - InterAksyon |
|
|
|
InterAksyon.com
The online news portal of TV5
MANILA - The Philippine Health Insurance Corporation (PhilHealth) has announced that coverage for hemodialysis is now expanded from 45 to 90 sessions per year in order to help lessen the financial burden of its members undergoing the treatment.
The PhilHealth Board of Directors approved the expansion due to the growing incidence of kidney diseases in the country and to respond to the increasing clamor from different stakeholders to increase PhilHealth coverage for hemodialysis.
“Based on a series of consultative meetings and dialogues with our stakeholders, our current coverage of P4,000 for hemodialysis is more than enough to cover the treatment cost per session, thus, we are adjusting the case rate amount to P2,500 per session but extending the number of sessions per year,” said PhilHealth President and CEO Alexander Padilla.
Padilla also explained that the reduction in the package amount will extend the members’ accessibility to the treatment of up to 90 sessions per year instead of the current maximum allowable sessions of 45 per year. “We want to assure our members that this adjustment will not in any way affect the quality of care being provided by our accredited facilities,” Padilla added.
With this new development, PhilHealth members including their qualified dependents undergoing dialysis treatment are ensured of longer sessions in a year thereby reducing out-of-pocket expenses to achieve better health outcomes. The adjusted PhilHealth coverage of P2,500 per session includes payment for facilities and professional fees of attending physicians.
PhilHealth records show that in 2014, hemodialysis posted the most number of filed claims among procedures at 691,489, with total benefit payments amounting to P4,666,806,642.
PhilHealth members can avail themselves of the benefit package at any of its accredited Free Standing Dialysis Centers and hospitals nationwide.
|
|
Miller Children's Unveils New Larry Helen Hoag Foundation Pediatric Urology ... - Long Beach Post |
|
|
|
Spina bifida patient, Elizabeth Nario, is joined by the Miller Children’s Pediatric Urology & Nephrology care team to officially unveil the new Larry & Helen Hoag Foundation Pediatric Urology & Nephrology Center.
At a ribbon-cutting ceremony on Thursday, June 18, Miller Children’s & Women’s Hospital Long Beach unveiled the new Larry & Helen Hoag Foundation Pediatric Urology & Nephrology Center – an outpatient center dedicated to providing comprehensive, multi-disciplinary urologic and renal care.
The Larry & Helen Hoag Foundation Pediatric Urology & Nephrology Center merges Miller Children’s urology and nephrology (renal) programs, making it one of the only comprehensive centers of its kind in Southern California. The consolidation of disciplines better serves patients in the prevention, diagnosis and treatment of kidney and urological diseases, while continuing to provide quality patient and family centered care and conduct innovative research.
The new Center was made possible by a generous lead gift from The Larry & Helen Hoag Foundation secured by the Memorial Medical Center Foundation, as well as proceeds from the 2014 Champions Club Spring Classic, an annual golf tournament held at the Virginia Country Club (VCC), led by VCC’s Jamie Mulligan and Whit Latimer, Memorial Medical Center Foundation board member.
Mrs. Hoag has been one of the leading philanthropists supporting Miller Children's for nearly a decade. In 2009, an endowment was established in her name to support the cleft lip and palate program at the Stramski Children’s Developmental Center at Miller Children’s. In 2010, Mrs. Hoag made a transformational gift to establish the Helen E. Hoag Endowed Chair in Pediatric Cardiovascular Surgery, a position that was filled by Shaun Setty, M.D. In addition, Mrs. Hoag has provided funds for capital equipment and research projects for a variety of programs at Miller Children’s.
“I want to express my appreciation to the Larry & Helen Hoag Foundation,” says Divya Joshi, M.D., MMM, chief medical officer, Miller Children’s. “Their generosity is why this center became a reality. This event marks the culmination of an idea that began more than two years ago – to create an innovative new center that gives our patients with urological and renal conditions the best possible care. Today, we have achieved that goal.”
 The Center features multiple large exam rooms, conference and consultation rooms for patients to speak privately with their physician and a procedure room. The procedure room has a dedicated C-arm – a minimally invasive imaging device, which allows for more cost-effective outpatient care and pain-reduced procedures.
The new Center puts Miller Children’s at the forefront of urological and renal care because of its ability to provide patients with unique treatment options and procedures ranging from identifying signs of fetal urologic anomalies in utero, to conducting reconstructive surgery using robotic techniques.
Marisol Barajas, District Director, Office of Assembly Member Patrick O’Donnell (right), presents Anne Tanner, executive director, Outpatient Specialty Centers, Miller Children’s (left), with a certificate marking the grand opening of the new Center.
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
